Folks across the Denver metro woke up to a humid, muggy morning Tuesday. What was up with that? Danielle Grant explains the ...

Novo Nordisk's market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company slashed its 2025 sales growth outlook due to ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Trump’s trade deal with the E.U. may lead to higher prices for brand-name drugs in the U.S., including Ozempic and Wegovy, ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk stock (NVO) (DK:NOVO.B) slumped 21.83% to fall to a new three-year low. It was the stock's worst daily loss since a 26.15% fall on Oct. 19, 1987. It's fallen 24.77% over the past two days ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook ...

The company now expects full-year sales growth of 8% to 14%, down significantly from 13% to 21%. Its guidance for operating ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...